Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia.
Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Viikinkaari 5E, Helsinki, 00014, Finland.
ChemMedChem. 2018 Jan 22;13(2):186-198. doi: 10.1002/cmdc.201700549. Epub 2018 Jan 8.
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes of antibacterial drugs that are unrepresented in the antibacterial pipeline. We developed 32 new N-phenylpyrrolamides and evaluated them against DNA gyrase and topoisomerase IV from E. coli and Staphylococcus aureus. Antibacterial activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent compound displayed an IC of 47 nm against E. coli DNA gyrase, and a minimum inhibitory concentration (MIC) of 12.5 μm against the Gram-positive Enterococcus faecalis. Some compounds displayed good antibacterial activities against an efflux-pump-deficient E. coli strain (MIC=6.25 μm) and against wild-type E. coli in the presence of efflux pump inhibitor PAβN (MIC=3.13 μm). Here we describe new findings regarding the structure-activity relationships of N-phenylpyrrolamide DNA gyrase B inhibitors and investigate the factors that are important for the antibacterial activity of this class of compounds.
ATP 竞争型 DNA 拓扑异构酶 II 和 IV 抑制剂是抗菌药物中最有趣的一类,但在抗菌药物研发中却没有涉及。我们开发了 32 种新的 N- 苯基吡咯烷酰胺,并对大肠杆菌和金黄色葡萄球菌的 DNA 拓扑异构酶 II 和 IV 进行了评估。研究了这些化合物对革兰氏阳性和革兰氏阴性细菌菌株的抗菌活性。最有效的化合物对大肠杆菌 DNA 拓扑异构酶 II 的 IC 为 47nm,对革兰氏阳性粪肠球菌的最小抑菌浓度(MIC)为 12.5μm。一些化合物对缺乏外排泵的大肠杆菌菌株表现出良好的抗菌活性(MIC=6.25μm),并在外排泵抑制剂 PAβN 存在的情况下对野生型大肠杆菌表现出抗菌活性(MIC=3.13μm)。在这里,我们描述了 N- 苯基吡咯烷酰胺 DNA 拓扑异构酶 IIB 抑制剂的构效关系的新发现,并研究了影响该类化合物抗菌活性的因素。